The Bone, Exercise, Alendronate, and Caloric Restriction (BEACON) Trial
Primary Objective
The purpose of this research is to identify strategies that minimize bone loss that occurs when older adults lose weight
Description
The purpose of this research study is to identify strategies that minimize bone loss that occurs when older adults lose weight. Your participation in this research study will involve a groupmediated weight loss intervention and may involve resistance training and/or 70 mg of weekly oral alendronate or placebo for 52 weeks. Alendronate is a medication that prevents bone breakdown and has been approved by the US Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in older men and women. In this study, a drug will be compared to a placebo. A placebo is a substance is a substance that is not thought to have any effect on your disease or condition. In this study you will either receive the active study medication, or placebo which is not active. Placebos are used in research studies to see if the drug being studied really does have an effect.
Details
Locations
Outpatient CTRC
Principal Investigator
Sarah Wherry
Study ID
Protocol Number: 22-2041
More information available at ClinicalTrials.gov: NCT05764733
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers